Cargando…

External validation of a tumor growth inhibition-overall survival model in non-small-cell lung cancer based on atezolizumab studies using alectinib data

BACKGROUND: A modeling framework was previously developed to simulate overall survival (OS) using tumor growth inhibition (TGI) data from six randomized phase 2/3 atezolizumab monotherapy or combination studies in non-small-cell lung cancer (NSCLC). We aimed to externally validate this framework to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kassir, Nastya, Chan, Phyllis, Dang, Steve, Bruno, René
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363035/ https://www.ncbi.nlm.nih.gov/pubmed/37410154 http://dx.doi.org/10.1007/s00280-023-04558-z

Ejemplares similares

Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition–overall survival modeling framework
por: Chan, Phyllis, et al.
Publicado: (2021)

Application of Machine Learning for Tumor Growth Inhibition – Overall Survival Modeling Platform
por: Chan, Phyllis, et al.
Publicado: (2020)

Tumor Time‐Course Predicts Overall Survival in Non‐Small Cell Lung Cancer Patients Treated with Atezolizumab: Dependency on Follow‐Up Time
por: Netterberg, Ida, et al.
Publicado: (2020)

Transformation of ALK-positive NSCLC to SCLC after alectinib resistance and response to combined atezolizumab: a case report
por: Xia, Guohao, et al.
Publicado: (2023)

Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1)
por: Wu, Benjamin, et al.
Publicado: (2021)

Development and External Validation of a Novel Immune Checkpoint–Related Gene Signature for Prediction of Overall Survival in Hepatocellular Carcinoma
por: Zhao, Enfa, et al.
Publicado: (2021)

External Validation of Robust Radiomic Signature to Predict 2-Year Overall Survival in Non-Small-Cell Lung Cancer
por: Jha, Ashish Kumar, et al.
Publicado: (2023)

Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC
por: Kim, Dong-Wan, et al.
Publicado: (2022)

Post‐progression survival after atezolizumab plus carboplatin and etoposide as first‐line chemotherapy in small cell lung cancer has a significant impact on overall survival
por: Masubuchi, Ken, et al.
Publicado: (2022)

Population Pharmacokinetics of Tenecteplase in Patients With Acute Myocardial Infarction and Application to Patients With Acute Ischemic Stroke
por: Tang, Fei, et al.
Publicado: (2022)

Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring STK11 or KEAP1 mutation
por: Nie, Wei, et al.
Publicado: (2021)

Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting
por: Morrissey, Kari M., et al.
Publicado: (2019)

Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
por: Liu, Stephen V., et al.
Publicado: (2021)

Pan‐cancer population pharmacokinetics and exposure‐safety and ‐efficacy analyses of atezolizumab in patients with high tumor mutational burden
por: Shemesh, Colby S., et al.
Publicado: (2020)

External validation of three prognostic models for overall survival in patients with advanced-stage epithelial ovarian cancer
por: van de Laar, R, et al.
Publicado: (2014)

Development and external validation of a nomogram predicting overall survival after curative resection of colon cancer
por: Wang, Shuanhu, et al.
Publicado: (2021)

Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)
por: Watanabe, Satoshi, et al.
Publicado: (2022)

Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer
por: Hotta, K., et al.
Publicado: (2022)

External validation of a prognostic score predicting overall survival for patients with brain metastases based on extracranial factors
por: Lewitzki, Victor, et al.
Publicado: (2019)

Development and External Validation of a Nomogram for Predicting Overall Survival in Stomach Cancer: A Population-Based Study
por: Ji, Haonan, et al.
Publicado: (2021)

Construction and External Validation of a Ferroptosis-Related Gene Signature of Predictive Value for the Overall Survival in Bladder Cancer
por: Liu, Jingchao, et al.
Publicado: (2021)

Machine Learning for Exposure-Response Analysis: Methodological Considerations and Confirmation of Their Importance via Computational Experimentations
por: Harun, Rashed, et al.
Publicado: (2023)

Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma
por: Tokunaga, Takayuki, et al.
Publicado: (2023)

Sequential treatment with alectinib in crizotinib-resistant non-small-cell lung cancer
por: Majumdar, Swaratika, et al.
Publicado: (2018)

Development and External Validation of a Novel 12-Gene Signature for Prediction of Overall Survival in Muscle-Invasive Bladder Cancer
por: Abudurexiti, MierXiati, et al.
Publicado: (2019)

Population Pharmacokinetics and Pharmacodynamics of Ontamalimab (SHP647), a Fully Human Monoclonal Antibody Against Mucosal Addressin Cell Adhesion Molecule‐1 (MAdCAM‐1), in Patients With Ulcerative Colitis or Crohn's Disease
por: Wang, Yi, et al.
Publicado: (2020)

Pharmacokinetics, Pharmacodynamics, and Exposure‐Response of Lanadelumab for Hereditary Angioedema
por: Wang, Yi, et al.
Publicado: (2020)

Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib
por: Morcos, Peter N., et al.
Publicado: (2018)

Nomogram development and external validation for predicting overall survival and cancer-specific survival in patients with primary retroperitoneal sarcoma: a retrospective cohort study
por: Zheng, Jialiang, et al.
Publicado: (2023)

Development and Validation of a Prognostic Model for Overall Survival in Patients with Primary Pelvis and Spine Osteosarcoma: A Population-Based Study and External Validation
por: Wang, Da, et al.
Publicado: (2023)

Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib
por: Muller, Ittai B, et al.
Publicado: (2017)

Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives
por: Karachaliou, Niki, et al.
Publicado: (2019)

External validation of the hospital frailty risk score among older adults receiving mechanical ventilation
por: Sy, Eric, et al.
Publicado: (2022)

Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2)
por: Peters, Solange, et al.
Publicado: (2021)

Development and external validation of a nomogram for predicting the overall survival of patients with stage II nasopharyngeal carcinoma after curative treatment
por: He, Sha-Sha, et al.
Publicado: (2019)

Development and external validation of a nomogram to predict overall survival following stereotactic body radiotherapy for early-stage lung cancer
por: Baker, Sarah, et al.
Publicado: (2020)

External Validation of a Nomogram Developed for Predicting Overall Survival in Gastric Cancer Patients with Insufficient Number of Examined Lymph Nodes
por: Kubat, Mehmet, et al.
Publicado: (2022)

Alectinib-Induced Erythema Multiforme and Successful Rechallenge with Alectinib in a Patient with Anaplastic Lymphoma Kinase-Rearranged Lung Cancer
por: Kimura, Tatsuo, et al.
Publicado: (2016)

Fibroblasts and Alectinib switch the evolutionary games played by non-small cell lung cancer
por: Kaznatcheev, Artem, et al.
Publicado: (2019)

Use of Atezolizumab for Bladder and Non–Small Cell Lung Cancers
por: Moore, Kayla Faith
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2i1bcnj4lkf3tgdvd1f4sbk7bq